Cohen, Placitella & Roth, PC is investigating claims on behalf of investors who purchased Galena Biopharma, Inc. (NASDAQ:GALE) stock between November 6, 2013 and February 14 2014, inclusive. The investigation concerns whether Galena disseminated materially false and/or misleading information to investors in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Galena Biopharma Inc. (NASDAQ:GALE) stock opened at $3.84 in last session, and closed at $3.46, while the day range of Galena Biopharma Inc. (NASDAQ:GALE) stock is $3.45 – $3.85. The stock showed a positive weekly performance of -10.13%.
Novavax (NASDAQ:NVAX) is scheduled to announce its Q413 earnings results on Monday, March 10th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $6.22 million for the quarter. Novavax, Inc. (NASDAQ:NVAX) stock opened at $6.35 in last session, and closed at $6.05 by losing -5.02%. The 52 week range of $1.68 – $6.95. Company’s market capitalization is $1.02 billion.
Repligen Corporation (NASDAQ:RGEN) announced that BioMarin Pharmaceutical has acquired the assets in the company’s Histone DeACetylase (HDAC) inhibitor program. Repligen Corporation (NASDAQ:RGEN) stock decreased -8.52% and finished the last session at $$14.17. The EPS of the stock remained 0.70. Company’s market capitalization is $451.43 million.
Equities research analysts at Jefferies Group raised their price target on shares of Celldex Therapeutics (NASDAQ:CLDX) from $29.00 to $31.00 in a research note issued to investors on Tuesday, Stock Ratings Network reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s price objective suggests a potential upside of 11.03% from the company’s current price. Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock opened the session at $27.90, and closed the session at $$26.37. The 52 week range of the Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock remained $$9.13 – $38.84 and the day range was $$25.80 – $27.91.
Leave a Reply